“Anatomic Pathology Market Report is set to have rapid growth due rising implementation of tissue-diagnostic related procedures in disease screening and favourable reimbursement policies at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Anatomic Pathology Market Forecast 2019-2029: By Application (Disease Diagnosis, Drug Discovery & Development), By Product & Services (Instruments, Consumables), By End Use, And Segment Forecasts.
The global Anatomic Pathology market is poised for rapid growth between 2019 and 2029. The increase in the incidence of chronic diseases, advances in technology and the increase in the geriatric population are some of the key factors driving market growth.
Advances in technology have witnessed the anatomical pathology market. For example, in November 2018, Greg Clark, business secretary of the UK government, announced that the consortium groups will gather to create five new pathology and digital imaging centers, using artificial intelligence to accelerate the diagnosis of diseases in the United Kingdom, bringing together representatives of various divisions of the sector.
Companies are making continuous efforts to develop advanced and up-to-date pathological equipment with regards to their design and ease of use. Furthermore, there have been several collaborations and agreements between key companies for the introduction of an effective portfolio in order to circumvent the challenges related to disease management.
Leading companies featured in the report include Thermo Fisher Scientific, Inc.; Cardinal Health, Inc.; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Sakura Finetek USA, Inc.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; NeoGenomics Laboratories, Inc.; BioGenex; and Bio SB.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.
04 December 2019
Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.
04 December 2019
The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
04 December 2019
Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.